Orphan Drugs and Rare Diseases Conference

Memo

This year's SMi's Orphan Drugs and Rare Diseases Conference will bring together regulatory agencies, pharmaceutical companies, non-profit organisations and orphan drugs developers to construct an agenda that addresses the driving economic factors, policies and issues that will affect the development of orphan drugs globally including commercialisation, policies, reimbursement, and pricing.



Keep up to date with the industry and to learn from expert speaker panel, bringing you important new case studies and reports on this year’s relevant topics.



HIGHLIGHTS IN 2018:

Discuss the pricing and reimbursement of orphan drugs

Understand the challenges of patient recruitment and patient-centric research

Hear the MHRA's perspective on benefit-risk assessment in rare diseases

Explore the clinical development of orphan drugs for rare disease

Gain insight into potential synergies between regulators and assessors





SPEAKERS INCLUDE:

Carina Schey, Researcher, University of Groningen

Sheela Upadhyaya, Associate Director, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE)

Xavier Ortega, Project Manager, Rare Diseases, Minoryx

Nigel Nicholls, Director and Country Manager UK/Ireland, BioMarin Europe Ltd

Yolanda Barbachano, Senior Statistical Assessor, MHRA

Michale Bouskila-Chubb, Head of Business Development, Healx.



Brochure: https://go.evvnt.com/229976-2?pid=5569



Time: 08:00 to 17:00.



Venue details: Holiday Inn London - Kensington Forum, 97 Cromwell Road, Greater London, SW7 4DN, United Kingdom.



Price:

Orphan Drugs and Rare Diseases Conference - Main Conference | STANDARD PRICE: GBP 1499.0